发展中国家真实世界研究:NOACs与华法林在非瓣膜性房颤中的疗效与安全性比较
泰国9家医院2012年1月至2018年4月纳入2055例非瓣膜性房颤患者,比较NOACs与华法林的真实世界疗效与安全性。华法林组TTR中位数仅49.5%,NOACs组大出血风险显著降低(调整HR 0.46,95%CI 0.34-0.62)。与TTR低的华法林使用者相比,阿哌沙班和达比加群酯还降低血栓栓塞风险。
要点
- 华法林抗凝控制欠佳(TTR中位数49.5%)时,NOACs大出血风险显著低于华法林。
- 与TTR低的华法林相比,阿哌沙班和达比加群酯降低血栓栓塞风险。
- NOACs在抗凝质量欠佳医疗体系中的疗效与安全性优势更明显。
核心结论
- 在华法林抗凝控制欠佳的医疗体系中,NOACs使用与大出血风险大幅降低相关。
- 与TTR低的华法林使用者相比,NOACs的疗效和安全性优势更明显。
研究设计与样本
- 泰国9家医院2012年1月至2018年4月的真实世界研究,纳入2055例非瓣膜性房颤患者。
- 华法林605例,利伐沙班604例,达比加群酯441例,阿哌沙班405例。
- 采用倾向评分加权平衡组间协变量,Cox回归比较血栓栓塞、大出血和净不良临床事件风险。
主要发现
- 华法林使用者TTR中位数为49.5%(四分位距26.6%-70.3%)。
- 与华法林相比,NOACs整体分析大出血调整HR为0.46(95%CI 0.34-0.62),各药物单独分析亦一致。
- 与TTR低的华法林使用者相比,阿哌沙班血栓栓塞调整HR为0.48(95%CI 0.26-0.86,P=0.013)。
- 与TTR低的华法林使用者相比,达比加群酯血栓栓塞调整HR为0.44(95%CI 0.21-0.90,P=0.025)。
- 阿哌沙班和达比加群酯还与大出血风险显著降低相关。
临床怎么用
- 在华法林抗凝质量控制不佳的机构,可优先考虑NOACs以降低大出血风险。
- 对TTR低的房颤患者,换用阿哌沙班或达比加群酯可能进一步降低血栓栓塞风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to compare effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) in a developing country where anticoagulation control with warfarin is suboptimal. A real-world study was conducted among patients with NVAF in Thailand receiving NOACs and warfarin from 9 hospitals during January 2012 to April 2018. Propensity-score weighting was used to balance covariates across study groups. Cox regression models were used to compare the risk of thromboembolism, major bleeding, and net adverse clinical events across matched cohorts. A total of 2,055 patients; 605, 604, 441, and 405 patients receiving warfarin, rivaroxaban, dabigatran, and apixaban, respectively, were included. Median (interquartile range) time in therapeutic range (TTR) for warfarin users was 49.5% (26.6%-70.3%). Compared with warfarin, NOACs were associated with a significant reduction in major bleeding either when analyzed as a group (adjusted hazard ratio (HR) (95% confidence interval (CI)) of 0.46 (0.34-0.62) or by each agent. Compared with warfarin users with poor TTR, apixaban (adjusted HR 0.48, 95% CI 0.26-0.86, P = 0.013) and dabigatran (adjusted HR 0.44, 95% CI 0.21-0.90, P = 0.025) were associated with a lower risk of thromboembolism, in addition to markedly lower risk of major bleeding. In a healthcare system where anticoagulation control with warfarin is suboptimal, use of NOACs was associated with a profound reduction in major bleeding. The effectiveness and safety advantages of NOACs were more pronounced compared with warfarin users with low TTR.
引用
- Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, et al. Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. Clin Pharmacol Ther. 2020. PMID: 33113153. doi:10.1002/cpt.2090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。